Aura BiosciencesAURA
AURA
About: Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Employees: 106
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0.37% more ownership
Funds ownership: 78.98% [Q4 2024] → 79.35% (+0.37%) [Q1 2025]
0% more funds holding
Funds holding: 94 [Q4 2024] → 94 (+0) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 30
5% less call options, than puts
Call options by funds: $36K | Put options by funds: $38K
29% less capital invested
Capital invested by funds: $324M [Q4 2024] → $232M (-$92.7M) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$19
196%
upside
Avg. target
$21
231%
upside
High target
$25
289%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Andres Maldonado | 243%upside $22 | Buy Assumed | 28 May 2025 |
JMP Securities Jonathan Wolleben | 196%upside $19 | Market Outperform Reiterated | 23 May 2025 |
Citizens Capital Markets Jonathan Wolleben | 196%upside $19 | Market Outperform Maintained | 26 Mar 2025 |
HC Wainwright & Co. Edward White | 289%upside $25 | Buy Maintained | 25 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 11,735,565 shares of its common stock and accompanying warrants to purchase an aggregate of 2,933,891 shares of common stock and (ii) to certain investors, pre-funded warrants to purchase an aggregate of up to 3,571,435 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant, and accompanying warrants to purchase up to 892,858 shares of its common stock. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase 0.25 of a share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying common stock warrant has an exercise price of $4.90 per share, is immediately exercisable from the date of issuance and will expire five years from the date of issuance. The combined offering price of each share of common stock and accompanying common stock warrant is $4.90. The combined offering price of each pre-funded warrant and accompanying common stock warrant is $4.89999.
Neutral
GlobeNewsWire
1 month ago
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying warrants to purchase shares of its common stock. All of the shares of common stock, pre-funded warrants and accompanying common stock warrants to be sold in the offering will be offered by Aura. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Neutral
GlobeNewsWire
1 month ago
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights
First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025
Neutral
GlobeNewsWire
1 month ago
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
2 months ago
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company's Board of Directors, effective March 31, 2025.
Neutral
Seeking Alpha
2 months ago
Aura Biosciences, Inc (AURA) Virtual Urologic Oncology Investor Event Call (Transcript)
Aura Biosciences, Inc (NASDAQ:AURA ) Virtual Urologic Oncology Investor Event Conference Call March 24, 2025 4:30 PM ET Company Participants Jill Hopkins - Chief Medical Officer & President of R&D Sabine Brookman-May - Senior Vice President, Therapeutic Area Head Urologic Oncology Joseph McQuaid - Clinical Lead, Urologic Oncology Jennifer Linehan - St. John's Cancer Institute Neal Shore - Carolina Urologic Research Center Gary Steinberg - Professor, Department of Urology at Rush University in Chicago Conference Call Participants Andy Berens - Leerink Philip Nadeau - TD Cowen Oliver McCammon - LifeSci Capital Jon Wolleben - JMP Securities George Farmer - Scotiabank Operator Good afternoon, and welcome to the Aura Biosciences Virtual Urologic Oncology Investor Event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Aura website following the conclusion of the event.
Neutral
GlobeNewsWire
2 months ago
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential
Neutral
GlobeNewsWire
2 months ago
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress
Clinical Complete Responses Observed with Single Low-Dose of Bel-sar in Patients with Intermediate and High-Risk NMIBC with Robust Cell-Mediated Immunity and Urothelial Field Effect
Neutral
GlobeNewsWire
3 months ago
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress
Aura will Participate in the Research Forum at the 40th Annual European Association of Urology Congress Aura will Host a Virtual Urologic Oncology Investor Event Featuring Key Opinion Leaders at 4:30 pm Eastern Time on March 24, 2025 BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that additional Phase 1 data evaluating bel-sar (AU-011) for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) will be presented at the 40th Annual European Association of Urology (EAU) Congress being held March 21-24, 2025, in Madrid, Spain. Aura will also participate in the EAU Research Forum during the Congress.
Neutral
GlobeNewsWire
3 months ago
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:
Charts implemented using Lightweight Charts™